Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 13/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10283789 | 0.91 | SLC22A2 (0.56) | SLC22A2CYP3A4TMEM97ABCG2POU2F2 | |
| SCHEMBL93099 | 0.91 | SLC22A2 (0.56) | SLC22A2CYP3A4TMEM97ABCG2POU2F2 | |
| SCHEMBL93037 | 0.90 | SLC22A2 (0.56) | SLC22A2CYP3A4TMEM97ABCG2POU2F2 | |
| SCHEMBL93098 | 0.90 | SLC22A2 (0.54) | SLC22A2CYP3A4TMEM97ABCG2POU2F2 | |
| SCHEMBL93036 | 0.89 | SLC22A2 (0.53) | SLC22A2CYP3A4TMEM97ABCG2POU2F2 | |
| SCHEMBL93038 | 0.89 | SLC22A2 (0.59) | SLC22A2CYP3A4TMEM97ABCG2POU2F2 | |
| SCHEMBL10284205 | 0.89 | SLC22A2 (0.54) | SLC22A2CYP3A4TMEM97ABCG2POU2F2 | |
| SCHEMBL10283457 | 0.87 | SLC22A2 (0.59) | SLC22A2CYP3A4TMEM97ABCG2POU2F2 | |
| SCHEMBL93001 | 0.85 | SLC22A2 (0.54) | SLC22A2CYP3A4TMEM97ABCG2POU2F2 | |
| SCHEMBL93065 | 0.83 | SLC22A2 (0.55) | SLC22A2CYP3A4TMEM97ABCG2POU2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224695-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-8129385-B2 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | VIIV HEALTHCARE COMPANY | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224695-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NCOA4, NR4A1, NR4A2 | SLC22A2 3012/4885CYP3A4 26/4885TMEM97 3407/4885 |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | NR4A1, NCOA4, NR4A2 | SLC22A2 2976/4885CYP3A4 28/4885TMEM97 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.